Key Takeaways:

• The funding round was co-led by BOLD and the US-based hedge fund Weiss Asset Management.
• The investment highlights growing interest in biotechnology-driven beauty innovation.
• This strategic collaboration combines OliX’s world-class siRNA platform capabilities with L’Oréal’s commitment to beauty innovation.

South Korean biotech company OliX Pharmaceuticals, a leading developer of RNAi therapeutics, today announced that it has raised $71 million, co-led by BOLD and Weiss Asset Management.

WHO: OliX is a biotechnology company focused on the development of innovative therapeutics that regulate disease-causing gene expression based on RNA interference (RNAi) technology. Leveraging RNAi technology, OliX is researching and developing therapeutics for a broad range of diseases, with multiple pipeline programs currently in clinical stages.

OliX is developing therapeutics using its proprietary core drug development platform, OASIS (OliX Advanced Small Interfering RNA System), which enhances RNAi's high gene-silencing efficiency and enables tissue-specific delivery. Based on this platform, OliX is advancing locally administered RNAi therapeutics for various indications, including hair loss, age-related macular degeneration (AMD), and hypertrophic scars. In addition, by incorporating hepatocyte-specific delivery technology, OliX is building pipelines in liver-related diseases, including metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders.

In accordance with its mid- to long-term growth strategy, the “OliX 2.0 Roadmap,” OliX will continue to expand the application of RNAi therapeutics. The company is building novel...